Rhelion Life Sciences Announces Filament Health is Planning a Stability Program for IBEX011, Its Naturally Derived Ibogaine Drug Candidate
Toronto, Ontario--(. - September 10, 2026) - Rhelion Life Sciences Corp. CSE:RHEL (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsidiary Filament He…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.